ArticleFrontiers in pharmacology2026
Furmonertinib demonstrated efficacy in a case of advanced pancreatic cancer with a 19-exon deletion mutation and wild-type KRAS: a case report and literature review.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In China, advanced pancreatic cancer (PC) is known as the "king of cancers" due to its high treatment difficulty and extremely short survival period. Currently, advanced pancreatic cancer is mainly treated with chemotherapy. The 5-year survival rate is approximately 14.4% for patients with locally advanced pancreatic cancer and only 3% for those with distant metastasis. There are currently no effective targeted drugs for pancreatic cancer. This article reports a case of a patient with advanced pancreatic cancer harboring an EGFR exon 19 deletion. The patient received furmonertinib as third-line therapy, achieving a progression-free survival (PFS) of 6.3 months. Subsequently, drug resistance occurred; increasing the dose of furmonertinib showed no efficacy. Later, a combination of furmonertinib and anlotinib was administered, which successfully overcame the resistance. After follow-up, the patient passed away at home on 22 January 2026. The overall survival time was approximately 38 months. This case suggests that furmonertinib may be effective in patients with pancreatic cancer patients harboring an EGFR exon 19 deletion and that the combination of anlotinib and furmonertinib may overcome resistance to furmonertinib. This is only a case report, and these findings warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.